# Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

> **NCT00522392** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00522392
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2012-08
- **Final completion:** 2014-07
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2015-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522392, "Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00522392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*